Caris' Precision Oncology Alliance Continues to Grow Internationally as it Welcomes Curie Oncology from Singapore Curie Oncology expands Caris' collaborative network of oncology institutions focused on research into personalized therapies through precision medicine News provided by Share this article IRVING, Texas, March 9, 2021 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that Curie Oncology from Singapore has joined Caris' Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve clinical outcomes of cancer patients.